Magdalena B Skarzynska1,2, Aleksandra Kolodziejak3, Elżbieta Gos3, Piotr H Skarzynski1,3,4. 1. Institute of Sensory Organs, 05-830 Warsaw, Poland. 2. Center of Hearing and Speech Medincus, 05-830 Warsaw, Poland. 3. Department of Teleaudiology and Screening, World Hearing Center, Institute of Physiology and Pathology of Hearing, 05-830 Warsaw, Poland. 4. Heart Failure and Cardiac Rehabilitation Department, Faculty of Medicine, Medical University of Warsaw, 03-242 Warsaw, Poland.
Abstract
BACKGROUND: A prospective clinical study was conducted to investigate whether two different pharmacotherapy strategies of steroid administration impact hearing preservation in adult patients who underwent cochlear implantation with the Oticon Medical Neuro cochlear implant system. METHODS: Twenty nine adult participants were included. Pure tone audiometry was performed before implantation, during processor activation and 12 months after activation. There were three treatment groups: (1) intravenous steroid therapy (standard steroid therapy with dexamethasone administrated intravenously at the dose 0.1 mg/kg body mass twice a day); (2) combined oral and intravenous steroid therapy (extended steroid therapy with dexamethasone administrated intravenously at the dose 0.1 mg/kg b.m. twice a day and prednisone (orally) at the dose 1 mg/kg body mass/24 h), and (3) no steroid therapy (a control group). Patients' hearing thresholds before implantation were on average 103 dB HL, 89 dB HL, and 93 dB HL, respectively. RESULTS: Deterioration of hearing thresholds was observed in all three patients' groups. Twelve months after surgery the patients with and without steroid therapy had similar hearing thresholds. CONCLUSIONS: The steroid regimen used in this study did not play a significant role in patients with non-functional residual hearing, who underwent cochlear implantation with the Oticon Medical Neuro cochlear implant system.
BACKGROUND: A prospective clinical study was conducted to investigate whether two different pharmacotherapy strategies of steroid administration impact hearing preservation in adult patients who underwent cochlear implantation with the Oticon Medical Neuro cochlear implant system. METHODS: Twenty nine adult participants were included. Pure tone audiometry was performed before implantation, during processor activation and 12 months after activation. There were three treatment groups: (1) intravenous steroid therapy (standard steroid therapy with dexamethasone administrated intravenously at the dose 0.1 mg/kg body mass twice a day); (2) combined oral and intravenous steroid therapy (extended steroid therapy with dexamethasone administrated intravenously at the dose 0.1 mg/kg b.m. twice a day and prednisone (orally) at the dose 1 mg/kg body mass/24 h), and (3) no steroid therapy (a control group). Patients' hearing thresholds before implantation were on average 103 dB HL, 89 dB HL, and 93 dB HL, respectively. RESULTS: Deterioration of hearing thresholds was observed in all three patients' groups. Twelve months after surgery the patients with and without steroid therapy had similar hearing thresholds. CONCLUSIONS: The steroid regimen used in this study did not play a significant role in patients with non-functional residual hearing, who underwent cochlear implantation with the Oticon Medical Neuro cochlear implant system.
Authors: Cristina Maria Blebea; Laszlo Peter Ujvary; Violeta Necula; Maximilian George Dindelegan; Maria Perde-Schrepler; Mirela Cristina Stamate; Marcel Cosgarea; Alma Aurelia Maniu Journal: Medicina (Kaunas) Date: 2022-05-31 Impact factor: 2.948
Authors: Magdalena Beata Skarzynska; Aleksandra Kolodziejak; Elżbieta Gos; Piotr Henryk Skarzynski; Artur Lorens; Adam Walkowiak Journal: Life (Basel) Date: 2022-03-27
Authors: Cristina Maria Blebea; Violeta Necula; Monica Potara; Maximilian George Dindelegan; Laszlo Peter Ujvary; Emil Claudiu Botan; Alma Aurelia Maniu; Marcel Cosgarea Journal: Audiol Res Date: 2022-08-28